Albert David Limited ALBERTDAVD NSEPHARMA
Healthcare · Drug Manufacturers - Specialty & Generic · India
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.
READ MORE ›₹708.45
-11.60% 1Y
Market & Price
Market Cap
₹404.32 Cr
Current Price
₹708.45
High / Low (52W)
₹941.36 / ₹587.05
Beta
0.27
Valuation
Stock P/E
-
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹686.10
Price to Book
1.03
P/S
1.21
EV/EBITDA
32.20
Dividend Yield
0.71%
Profitability & Returns
ROCE
0.78%
ROE
-0.38%
ROA
-0.52%
Profit Margin
-0.45%
Op Margin
0.04%
EPS (Latest Qtr)
₹-37.56
EPS (TTM)
₹-2.62
Balance Sheet & Liquidity
Debt/Equity
0.08
Quick Ratio
2.53
Current Ratio
3.24
Debt
₹29.58 Cr
Total Assets
₹519.13 Cr
Current Assets
₹374.40 Cr
Working Capital
₹258.97 Cr
Ownership
Promoter Holding
64.04%
Chg in Prom Hold
-
FII / Inst Holding
1.61%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹176.05 Cr
Total Revenue (TTM)
₹333.60 Cr
EBITDA
₹5.47 Cr
Free Cash Flow
₹-36.86 Cr
Operating Cash Flow
₹-7.66 Cr
Shares Outstanding
₹57.07 L
Gross Margin
65.87%
Payout Ratio
29.69%
Growth (CAGR)
Revenue 5Y
-0.63%
Profit 5Y
-34.71%
Revenue (YoY)
14.60%
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Revenue declined at -0.6% CAGR over 5 years.
- Earnings shrank at -34.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALBERTDAVD Albert David Limited NSEPHARMA | 708.45 | - | ₹404.32 Cr | 0.71% | 0.78% | -0.38% | -0.63% | -34.71% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 74.89 Cr | 70.57 Cr | 87.24 Cr | 89.93 Cr | 85.86 Cr |
| Cost of Revenue | - | - | 29.33 Cr | 25.28 Cr | 30.65 Cr | 27.83 Cr | 30.10 Cr |
| Gross Profit | - | - | 45.57 Cr | 45.29 Cr | 56.59 Cr | 62.09 Cr | 55.77 Cr |
| Operating Expenses | - | - | 52.13 Cr | 58.33 Cr | 56.28 Cr | 53.69 Cr | 55.73 Cr |
| Operating Income | - | - | -6.56 Cr | -13.04 Cr | 31.24 L | 8.40 Cr | 3.37 L |
| EBITDA | - | - | -9.86 Cr | 11.38 Cr | 39.68 L | 23.22 Cr | -22.08 Cr |
| Interest Expense | - | - | 13.15 L | 55.48 L | 75.07 L | 89.77 L | 42.91 L |
| Pretax Income | - | - | -11.81 Cr | 8.44 Cr | -2.58 Cr | 19.90 Cr | -25.23 Cr |
| Tax Provision | - | - | -1.48 Cr | 50.07 L | 71.96 L | 4.60 Cr | -3.80 Cr |
| Net Income | - | - | -10.33 Cr | 7.94 Cr | -3.30 Cr | 15.30 Cr | -21.43 Cr |
| Diluted EPS | 31.67 | - | -18.10 | 13.91 | -5.79 | 26.81 | -37.56 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 340.01 Cr | 360.26 Cr | 345.77 Cr | 333.60 Cr |
| Cost of Revenue | - | 125.68 Cr | 128.40 Cr | 116.28 Cr | 113.86 Cr |
| Gross Profit | - | 214.33 Cr | 231.86 Cr | 229.48 Cr | 219.74 Cr |
| Operating Expenses | - | 177.78 Cr | 190.81 Cr | 233.43 Cr | 224.03 Cr |
| Operating Income | - | 36.54 Cr | 41.05 Cr | -3.94 Cr | -4.30 Cr |
| EBITDA | - | 59.62 Cr | 104.32 Cr | 32.61 Cr | 12.92 Cr |
| Interest Expense | - | 34.00 L | 20.72 L | 41.04 L | 2.63 Cr |
| Pretax Income | - | 50.74 Cr | 97.29 Cr | 25.23 Cr | 52.49 L |
| Tax Provision | - | 14.56 Cr | 21.87 Cr | 8.03 Cr | 2.02 Cr |
| Net Income | - | 36.17 Cr | 75.42 Cr | 17.20 Cr | -1.49 Cr |
| Diluted EPS | - | 63.39 | 132.15 | 30.14 | -2.62 |
Compounded Sales Growth
| 5 Years: | -0.63% |
| 1 Year: | 14.60% |
Compounded Profit Growth
| 5 Years: | -34.71% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -11.60% |
| 6 Months: | -11.58% |
| 3 Months: | -2.38% |
| 1 Month: | -1.63% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 423.39 Cr | 497.99 Cr | 511.42 Cr | 519.13 Cr |
| Current Assets | - | 304.24 Cr | 371.63 Cr | 354.05 Cr | 374.40 Cr |
| Cash & Equivalents | - | 1.45 Cr | 5.44 Cr | 41.73 L | 29.91 L |
| Inventory | - | 50.68 Cr | 43.61 Cr | 63.90 Cr | 58.27 Cr |
| Receivables | - | 30.33 Cr | 29.33 Cr | 27.37 Cr | 33.92 Cr |
| Total Liabilities | - | 111.82 Cr | 115.01 Cr | 118.93 Cr | 127.60 Cr |
| Current Liabilities | - | 98.94 Cr | 99.05 Cr | 104.18 Cr | 115.43 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 5.32 Cr | 3.32 Cr | 12.32 Cr | 29.58 Cr |
| Total Equity | - | 311.57 Cr | 382.98 Cr | 392.48 Cr | 391.54 Cr |
| Shares Outstanding | - | 57.07 L | 57.07 L | 57.07 L | 57.07 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 10.52 Cr | 45.50 Cr | -28.44 Cr | -7.66 Cr |
| Investing Cash Flow | - | -5.00 Cr | -33.25 Cr | 23.30 Cr | -4.40 Cr |
| Financing Cash Flow | - | -6.36 Cr | -8.27 Cr | 11.03 L | 11.92 Cr |
| Capital Expenditure | - | -5.24 Cr | -10.87 Cr | -14.86 Cr | -29.11 Cr |
| Free Cash Flow | - | 5.28 Cr | 34.63 Cr | -43.29 Cr | -36.77 Cr |
| Net Change in Cash | - | -84.24 L | 3.98 Cr | -5.02 Cr | -13.67 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 63.0% | 64.4% | 66.4% | 65.9% |
| Operating Margin % | - | 10.7% | 11.4% | -1.1% | -1.3% |
| Net Margin % | - | 10.6% | 20.9% | 5.0% | -0.4% |
| ROE % | - | 11.6% | 19.7% | 4.4% | -0.4% |
| ROCE % | - | 11.3% | 10.3% | -1.0% | -1.1% |
Shareholding Pattern
Insiders
64.04%
Institutions
1.61%
Public Float
4.48%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALBERTDAVD
No recent headlines available.